Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Moperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Hydrocodone | Moperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Magnesium sulfate | The therapeutic efficacy of Moperone can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Moperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Moperone may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Mirtazapine | Moperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Orphenadrine | Moperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Moperone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Pramipexole | Moperone may increase the sedative activities of Pramipexole. |
| Ropinirole | Moperone may increase the sedative activities of Ropinirole. |
| Rotigotine | Moperone may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Moperone. |
| Sodium oxybate | Moperone may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Moperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Thalidomide | Moperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Moperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Moperone may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Moperone is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Moperone is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Moperone. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Moperone. |
| Sulpiride | Moperone may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Moperone. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Moperone. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Moperone. |
| Mequitazine | Moperone may increase the arrhythmogenic activities of Mequitazine. |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Moperone is combined with Tetrabenazine. |
| Deutetrabenazine | The risk or severity of adverse effects can be increased when Moperone is combined with Deutetrabenazine. |
| Ethanol | Moperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Moperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Moperone. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Moperone is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Moperone is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Moperone is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Moperone is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Moperone is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Moperone is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Moperone is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Moperone is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Moperone is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Moperone is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Moperone is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Moperone is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Moperone is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Moperone is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Moperone. |
| Indalpine | The risk or severity of adverse effects can be increased when Moperone is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Moperone is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Moperone is combined with Alaproclate. |
| Amitriptyline | The risk or severity of adverse effects can be increased when Amitriptyline is combined with Moperone. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Moperone. |
| Imipramine | The risk or severity of adverse effects can be increased when Imipramine is combined with Moperone. |
| Nortriptyline | The risk or severity of adverse effects can be increased when Nortriptyline is combined with Moperone. |
| Amoxapine | The risk or severity of adverse effects can be increased when Amoxapine is combined with Moperone. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Moperone. |
| Maprotiline | The risk or severity of adverse effects can be increased when Maprotiline is combined with Moperone. |
| Doxepin | The risk or severity of adverse effects can be increased when Doxepin is combined with Moperone. |
| Desipramine | The risk or severity of adverse effects can be increased when Desipramine is combined with Moperone. |
| Pizotifen | The risk or severity of CNS depression can be increased when Pizotifen is combined with Moperone. |
| Dosulepin | The risk or severity of adverse effects can be increased when Dosulepin is combined with Moperone. |
| Zopiclone | The risk or severity of adverse effects can be increased when Moperone is combined with Zopiclone. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Moperone. |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Moperone. |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Moperone. |
| Dihydroergotamine | The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Moperone. |
| Protriptyline | The risk or severity of adverse effects can be increased when Protriptyline is combined with Moperone. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Moperone. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Moperone. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Moperone. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Moperone. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Moperone. |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Moperone. |
| Trimipramine | The risk or severity of adverse effects can be increased when Trimipramine is combined with Moperone. |
| Tranylcypromine | The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moperone. |
| Phenelzine | The risk or severity of adverse effects can be increased when Phenelzine is combined with Moperone. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Moperone. |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Moperone. |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Moperone. |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Moperone. |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Moperone. |
| Selegiline | The risk or severity of adverse effects can be increased when Selegiline is combined with Moperone. |
| Ergoloid mesylate | The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Moperone. |
| Chlorpheniramine | The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Moperone. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Moperone. |
| Moclobemide | The risk or severity of adverse effects can be increased when Moclobemide is combined with Moperone. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Moperone. |
| Clomipramine | The risk or severity of adverse effects can be increased when Clomipramine is combined with Moperone. |
| Isocarboxazid | The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moperone. |
| Ergometrine | The risk or severity of adverse effects can be increased when Ergometrine is combined with Moperone. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Moperone. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Moperone. |
| Mianserin | The risk or severity of adverse effects can be increased when Mianserin is combined with Moperone. |